Navigation Links
Promising advances in islet cell transplants for diabetes
Date:6/9/2008

University of Illinois at Chicago researchers have modified the procedure for islet cell transplantation and achieved insulin independence in diabetes patients with fewer but better-functioning pancreatic islet cells.

The study results are published in the June issue of the American Journal of Transplantation.

UIC is one of only a few centers worldwide able to achieve reproducible and consistent insulin independence in severe type 1 diabetes patients.

In the UIC study, 10 patients with diabetes received between one and three islet cell transplants and were followed for 15 months.

Four received the Edmonton protocol, developed at the University of Alberta, which uses a combination of two immunosuppressants and a monoclonal antibody drug, daclizumab.

Six patients received the UIC protocol -- a combination of etanercept (an anti-inflammatory drug developed to treat rheumatoid arthritis) and exenatide (a drug approved for use in type 2 diabetes to improve glucose control) -- and the Edmonton regimen.

The new procedure allowed patients to get off insulin after a single transplant versus the two to four transplants that were needed using the older protocol, said Dr. Jos Oberholzer, director of cell and pancreas transplantation at UIC and lead author of the study.

All patients in the study achieved insulin independence, but those who received the UIC protocol required fewer than half the number of islets as those who were treated under the Edmonton protocol.

The four patients who received the Edmonton protocol needed either two or three sequential islet cell transplants to achieve insulin-independence.

The six patients who were treated using the UIC protocol initially achieved insulin-independence after only one islet transplant. Two of these patients required a second islet cell transplant, and one resumed insulin five months after the second transplant due to other complications.

Progress in islet cell transplantation has been limited by the shortage of donor organs, said Oberholzer, who is associate professor of surgery, bioengineering and endocrinology at UIC.

"This study is extremely promising and shows that we can achieve success with fewer islet cells, freeing patients from the need to check their insulin, even after 20 or 30 years of suffering from diabetes," he said.

UIC is one of seven federally funded National Institutes of Health Islet Cell Resource Centers across the country that provides researchers with human pancreatic islet cells for transplantation into diabetic patients and for basic science research on diabetes.

"We have proven that if you have the right team and the right environment you can achieve islet cell transplantation success in a very short time," said Oberholzer, who has led UIC's program since 2003.

Building on results from Oberholzer's study, UIC is participating in the Clinical Islet Transplant Consortium, funded by the NIH to identify the most effective combination of anti-rejection drugs to maximize islet engraftment while reducing toxic side-effects.


'/>"/>

Contact: Sherri McGinnis Gonzalez
smcginn@uic.edu
312-996-8277
University of Illinois at Chicago
Source:Eurekalert

Related medicine news :

1. Promising drug combination may help those with ocular melanoma that has spread
2. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
3. Molecule Promising Against Huntingtons Disease
4. Computerized training of working memory is a promising therapeutic strategy in ADHD
5. Baicalin might be a promising therapeutic tool for severe acute pancreatitis
6. Initial Evaluation of New Nucleus Removal Device Provides Promising Results
7. Promising new TB drug given special status by US and European regulators
8. New Drug Promising Against Tough-to-Treat Kidney Cancer
9. Einstein scientists treat cancer as an infectious disease -- with promising results
10. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
11. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...
(Date:10/12/2017)... ... 2017 , ... In the United States, single-family home owners ... New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is $7,000 ... property-tax rates, which contributes to the relatively lower cost of living in places ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm ... California Berkeley, and other leading institutions in announcing the launch of the ... change the way animals are raised for food. , Founding members of the ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease ... end of October . PhysicianOne Urgent Care is helping communities across ... Westchester, NY , by offering no-cost* flu shots through the end ... mandated by certain health insurance regulations. ... The best time to get a flu shot is by the end ...
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
Breaking Medicine Technology: